Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

NCT00699374 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1075

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: sunitinib malate
DRUG: sorafenib

Sponsor

Pfizer